Androgen Receptor Expression in Estrogen Receptor-Negative Breast Cancer. Immunohistochemical, Clinical, and Prognostic Associations, American Journal of Clinical Pathology, vol.120, issue.5, pp.725-756, 2003. ,
Accessed November 18, p.9780387884400, 2015. ,
Estrogen Receptor Alpha in Human Breast Cancer: Occurrence and Significance, Journal of Mammary Gland Biology and Neoplasia, vol.5, issue.3, pp.271-81, 2000. ,
DOI : 10.1023/A:1009594727358
AR-V7 and Resistance to Enzalutamide and Abiraterone in Prostate Cancer, The New England Journal of Medicine, vol.371, issue.11, pp.1028-1066, 2014. ,
Complete Response of Metastatic Androgen Receptor-Positive Breast Cancer to Bicalutamide: Case Report and Review of the Literature, Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 2014. ,
Infiltrating lobular carcinoma of the breast: tumor characteristics and clinical outcome, Breast Cancer Research, vol.8, issue.3, p.149, 2004. ,
DOI : 10.1002/1097-0142(197507)36:1<1::AID-CNCR2820360102>3.0.CO;2-4
Clinical verification of sensitivity to preoperative chemotherapy in cases of androgen receptor-expressing positive breast cancer, British Journal of Cancer, vol.18, issue.1, pp.14-20, 2016. ,
DOI : 10.5858/arpa.2013-0953-SA
Identification of Subtypes of Triple Negative Breast Cancer (TNBC) That Are Sensitive to CDK4/6 Inhibition, Journal of Clinical Oncology, vol.33, issue.11098, pp.147443-156, 2015. ,
Selective blockade of androgenic steroid synthesis by novel lyase inhibitors as a therapeutic strategy for treating metastatic prostate cancer, BJU International, vol.84, issue.9, pp.1241-1287, 2005. ,
DOI : 10.1016/0960-0760(94)90131-7
Characterization of ERG, AR and PTEN Gene Status in Circulating Tumor Cells from Patients with Castration-Resistant Prostate Cancer, Cancer Research, vol.69, issue.7, pp.2912-2930, 2009. ,
DOI : 10.1158/0008-5472.CAN-08-3667
FOXA1: master of steroid receptor function in cancer, The EMBO Journal, vol.209, issue.19, pp.3885-94, 2011. ,
DOI : 10.1038/emboj.2011.340
Sequence Analysis of Mutations and Translocations across Breast Cancer Subtypes, Nature, vol.486, issue.7403, pp.405-414, 2012. ,
Molecular apocrine differentiation is a common feature of breast cancer in patients with germline PTEN mutations, Breast Cancer Research, vol.15, issue.4, pp.10-1186, 2010. ,
DOI : 10.1038/nm.2000
URL : https://hal.archives-ouvertes.fr/inserm-00663724
Enzalutamide in Metastatic Prostate Cancer before Chemotherapy, The New England Journal of Medicine, vol.371, issue.5, pp.424-457, 2014. ,
FOXA1 Represses the Molecular Phenotype of Basal Breast Cancer Cells, Oncogene, vol.32, issue.5, pp.554-63, 2013. ,
Pathologic Complete Response As a Potential Surrogate for the Clinical Outcome in Patients With Breast Cancer After Neoadjuvant Therapy: A Meta-Regression of 29 Randomized Prospective Studies, Journal of Clinical Oncology, vol.32, issue.34, pp.3883-91, 2014. ,
DOI : 10.1200/JCO.2014.55.2836
How Basal Are Triple-Negative Breast Cancers?, International Journal of Cancer, vol.123, issue.1, pp.236-276, 2008. ,
E-Cadherin Is a Tumour/Invasion Suppressor Gene Mutated in Human Lobular Breast Cancers, The EMBO Journal, vol.14, issue.24, p.6107, 1995. ,
Disruption of androgen receptor signaling by synthetic progestins may increase risk of developing breast cancer, The FASEB Journal, vol.21, issue.10, pp.2285-93, 2007. ,
DOI : 10.1096/fj.06-7518com
Subtyping of Breast Cancer by Immunohistochemistry to Investigate a Relationship between Subtype and Short and Long Term Survival: A Collaborative Analysis of Data for 10,159 Cases from 12 Studies, PLoS Medicine, vol.12, issue.5, 2010. ,
DOI : 10.1371/journal.pmed.1000279.s011
Breast Cancer Prognosis and Occult Lymph Node Metastases, Isolated Tumor Cells, and Micrometastases, JNCI Journal of the National Cancer Institute, vol.102, issue.6, pp.410-435, 2010. ,
DOI : 10.1093/jnci/djq008
p53 as a potential predictive factor of response to chemotherapy: feasibility of p53 assessment using a functional test in yeast from trucut biopsies in breast cancer patients, British Journal of Cancer, vol.1, issue.5, pp.750-55, 2002. ,
DOI : 10.1038/sj.bjc.6600105
A phase II trial of abiraterone acetate plus prednisone in patients with triple-negative androgen receptor positive locally advanced or metastatic breast cancer (UCBG 12-1), Annals of Oncology, vol.27, issue.5, pp.812-830, 2016. ,
DOI : 10.1093/annonc/mdw067
TP53 status for prediction of sensitivity to taxane versus non-taxane neoadjuvant chemotherapy in breast cancer (EORTC 10994/BIG 1-00): a randomised phase 3 trial, The Lancet Oncology, vol.12, issue.6, pp.527-566, 2011. ,
DOI : 10.1016/S1470-2045(11)70094-8
Activating HER2 Mutations in HER2 Gene Amplification Negative Breast Cancer, Cancer Du Sein Infiltrant Non Métastatique -Questions D'actualités (Annexes) -Ref, pp.224-261, 2013. ,
DOI : 10.1158/2159-8290.CD-12-0349
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3570596
http://www.ecancer.fr/Expertises-et-publications/Catalogue-des-publications/Cancer-du-sein-infiltrant- non-metastatique-questions-d-actualites-annexes ,
ESO-ESMO 2nd International Consensus Guidelines for Advanced Breast Cancer (ABC2), Annals of Oncology, 2014. ,
DOI : 10.1016/j.breast.2014.08.009
URL : http://doi.org/10.1016/j.breast.2014.08.009
Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases, Cancer, vol.45, issue.1, pp.181-87, 1989. ,
DOI : 10.1002/1097-0142(19890101)63:1<181::AID-CNCR2820630129>3.0.CO;2-H
Reciprocal Feedback Regulation of PI3K and Androgen Receptor Signaling in PTEN-Deficient Prostate Cancer, Cancer Cell, vol.19, issue.5, pp.575-86, 2011. ,
DOI : 10.1016/j.ccr.2011.04.008
Ki67 Index, HER2 Status, and Prognosis of Patients With Luminal B Breast Cancer, JNCI Journal of the National Cancer Institute, vol.101, issue.10, pp.736-50, 2009. ,
DOI : 10.1093/jnci/djp082
Responsiveness of Intrinsic Subtypes to Adjuvant Anthracycline Substitution in the NCIC.CTG MA.5 Randomized Trial, Clinical Cancer Research: An Official Journal of the American Association for Cancer Research, vol.18, issue.8, pp.2402-2414, 2012. ,
A Feedback Loop between Androgen Receptor and ERK Signaling in Estrogen Receptor-Negative Breast Cancer, Neoplasia, vol.13, issue.2, pp.154-66, 2011. ,
DOI : 10.1593/neo.101324
Targeting the Androgen Receptor in Breast Cancer, Current Oncology Reports, vol.14, issue.4, pp.4-10, 2015. ,
DOI : 10.1007/s11912-014-0427-8
Androgen Receptor Expression Predicts Decreased Survival in Early Stage Triple-Negative Breast Cancer, Annals of Surgical Oncology, vol.6, issue.1, pp.82-89, 2015. ,
DOI : 10.1245/s10434-014-3984-z
Clinicopathologic Features of Molecular Subtypes of Triple Negative Breast Cancer Based on Immunohistochemical Markers, Histology and Histopathology, vol.27, issue.11, pp.1481-93, 2012. ,
Lobular breast cancer: molecular basis, mouse and cellular models, Breast Cancer Research, vol.10, issue.1, 2015. ,
DOI : 10.1371/journal.pgen.1004285
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4320436
Androgen receptor promotes tamoxifen agonist activity by activation of EGFR in ER??-positive breast cancer, Breast Cancer Research and Treatment, vol.66, issue.Suppl 1, pp.225-262, 2015. ,
DOI : 10.1007/s10549-015-3609-7
ARN-509: A Novel Antiandrogen for Prostate Cancer Treatment, Cancer Research, vol.72, issue.6, pp.1494-1503, 2012. ,
DOI : 10.1158/0008-5472.CAN-11-3948
Senn, and Panel members Tailoring Therapies -Improving the Management of Early Breast Cancer: St GallenInternational Expert Consensus on the Primary Therapy of Early Breast Cancer 2015, Annals of Oncology: Official Journal of the European Society for Medical Oncology / ESMO, 2015. ,
Role of the androgen receptor in breast cancer and preclinical analysis of enzalutamide, Breast Cancer Research, vol.3, issue.1, 2014. ,
DOI : 10.1158/2159-8290.CD-13-0142
Outcome of Special Types of Luminal Breast Cancer, Annals of Oncology: Official Journal of the European Society for Medical Oncology / ESMO, vol.23, issue.6, pp.1428-1464, 2012. ,
Androgen receptor expression in breast cancer in relation to molecular phenotype: results from the Nurses' Health Study, Modern Pathology, vol.10, issue.7, pp.924-955, 2011. ,
DOI : 10.1093/jnci/djp082
Antiproliferative actions of the synthetic androgen, mibolerone, in breast cancer cells are mediated by both androgen and progesterone receptors, The Journal of Steroid Biochemistry and Molecular Biology, vol.110, issue.3-5, pp.3-5, 2008. ,
DOI : 10.1016/j.jsbmb.2007.10.014
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis, The Lancet, vol.384, issue.9938, pp.164-72, 2014. ,
DOI : 10.1016/S0140-6736(13)62422-8
High Ki-67 score is indicative of a greater benefit from adjuvant chemotherapy when added to endocrine therapy in Luminal B HER2 negative and node-positive breast cancer, The Breast, vol.23, issue.1, pp.69-75, 2014. ,
DOI : 10.1016/j.breast.2013.11.007
Phospho-kinase profile of triple negative breast cancer and androgen receptor signaling, BMC Cancer, vol.13, issue.1, pp.302-312, 2014. ,
DOI : 10.1186/bcr2858
Effect of Anastrozole and Tamoxifen as Adjuvant Treatment for Early-Stage Breast Cancer: 10-Year Analysis of the ATAC Trial, The Lancet. Oncology, vol.11, issue.1210, pp.1135-1176, 2010. ,
Aberrant Expression of E-cadherin in Lobular Carcinomas of the Breast, The American Journal of Surgical Pathology, vol.32, issue.5, pp.773-83, 2008. ,
DOI : 10.1097/PAS.0b013e318158d6c5
Population-based study of breast cancer survival in Cote d'Or (France): prognostic factors and relative survival, Annals of Oncology, vol.19, issue.2, pp.276-83, 2008. ,
DOI : 10.1093/annonc/mdm491
Long-Term Effects of Continuing Adjuvant Tamoxifen to 10, 2013. ,
Androgen receptor overexpression induces tamoxifen resistance in human breast cancer cells, Breast Cancer Research and Treatment, vol.90, issue.10, pp.1-11, 2010. ,
DOI : 10.1007/s10549-009-0436-8
Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12???155 patients, British Journal of Cancer, vol.27, issue.10, pp.1504-1517, 2007. ,
DOI : 10.1002/1097-0142(19910115)67:2<421::AID-CNCR2820670217>3.0.CO;2-Q
Obvious Peritumoral Emboli: An Elusive Prognostic Factor Reappraised. Multivariate Analysis of 1320 Node-Negative Breast Cancers, European Journal of Cancer, vol.34, issue.1, pp.58-65, 1990. ,
Concordance of Clinical and Molecular Breast Cancer Subtyping in the Context of Preoperative Chemotherapy Response, Breast Cancer Research and Treatment, vol.119, issue.1, pp.119-145, 2010. ,
URL : https://hal.archives-ouvertes.fr/hal-00535389
Axillary Dissection Can Be Avoided in the Majority of Clinically Node-Negative Patients Undergoing Breast-Conserving Therapy, Annals of Surgical Oncology, vol.205, issue.1, pp.22-27, 2014. ,
DOI : 10.1245/s10434-013-3200-6
Biological Processes Associated with Breast Cancer Clinical Outcome Depend on the Molecular Subtypes, Clinical Cancer Research, vol.14, issue.16, pp.5158-65, 2008. ,
DOI : 10.1158/1078-0432.CCR-07-4756
An estrogen receptor-negative breast cancer subset characterized by a hormonally regulated transcriptional program and response to androgen, Oncogene, vol.62, issue.28, pp.3994-4008, 2006. ,
DOI : 10.1038/sj.onc.1209415
Assessment of Ki67 in Breast Cancer: Recommendations from the International Ki67 in Breast Cancer Working Group, JNCI Journal of the National Cancer Institute, vol.103, issue.22, pp.1656-64, 2011. ,
DOI : 10.1093/jnci/djr393
Effect of Radiotherapy after Breast- Conserving Surgery on 10-Year Recurrence and 15-Year Breast Cancer Death: Meta-Analysis of Individual Patient Data for 10,801 Women in 17 Randomised Trials, Lancet, issue.980411, pp.378-1707, 2011. ,
Relevance of Breast Cancer Hormone Receptors and Other Factors to the Efficacy of Adjuvant Tamoxifen: Patient-Level Meta-Analysis of Randomised Trials, Lancet, issue.979311, pp.378-771, 2011. ,
Comparisons between Different Polychemotherapy Regimens for Early Breast Cancer: Meta-Analyses of Long-Term Outcome among 100, p.0, 2012. ,
Effect of Radiotherapy after Mastectomy and Axillary Surgery on 10-Year Recurrence and 20-Year Breast Cancer Mortality: Meta-Analysis of Individual Patient Data for 8135 Women in 22 Randomised Trials, EBCTCG (Early Breast Cancer Trialists' Collaborative Group), pp.383-2127, 2014. ,
Systematic Bias in Genomic Classification Due to Contaminating Non-neoplastic Tissue in Breast Tumor Samples, BMC Medical Genomics, vol.14, issue.10, pp.54-64, 2011. ,
DOI : 10.1158/1078-0432.CCR-07-4723
pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up, Histopathology, vol.9, issue.5, pp.403-413, 1991. ,
DOI : 10.1016/0277-5379(88)90171-X
Chemotherapy response and recurrence-free survival in neoadjuvant breast cancer depends on biomarker profiles: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657), Breast Cancer Research and Treatment, vol.102, issue.18, pp.1049-62, 2012. ,
DOI : 10.1007/s10549-011-1895-2
Identification of molecular apocrine breast tumours by microarray analysis, Oncogene, vol.268, issue.29, pp.4660-71, 2005. ,
DOI : 10.1023/A:1006356502820
Cancer incidence and mortality patterns in Europe: Estimates for 40 countries in 2012, European Journal of Cancer, vol.49, issue.6, pp.1374-1403, 2013. ,
DOI : 10.1016/j.ejca.2012.12.027
Prognostic Factors in Breast Cancer, College of American Pathologists Consensus Statement Archives of Pathology & Laboratory Medicine, vol.124, issue.7, pp.966-78, 1999. ,
Abiraterone Acetate for Treatment of Metastatic Castration-Resistant Prostate Cancer: Final Overall Survival Analysis of the COU-AA-301, 2012. ,
Placebo-Controlled Phase 3 Study, The Lancet Oncology, vol.13, issue.1012, pp.983-92 ,
Adjuvant Ovarian Suppression in Premenopausal Breast Cancer, New England Journal of Medicine, vol.372, issue.5, pp.436-482, 2015. ,
DOI : 10.1056/NEJMoa1412379
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4341825
Targeted inhibition of Hsp90 by ganetespib is effective across a broad spectrum of breast cancer subtypes, Investigational New Drugs, vol.3, issue.Suppl, pp.14-24, 2014. ,
DOI : 10.1007/s10637-013-9971-6
Immunohistochemical Analysis of Apocrine Breast Lesions. Consistent over-Expression of Androgen Receptor Accompanied by the Loss of Estrogen and Progesterone Receptors in Apocrine Metaplasia and Apocrine Carcinoma in Situ, Pathology, Research and Practice, vol.1931297, issue.11, pp.753-58, 1997. ,
DOI : 10.1016/s0344-0338(97)80053-2
Molecular Biology of the Androgen Receptor, Journal of Clinical Oncology, vol.20, issue.13, pp.3001-3016, 2002. ,
DOI : 10.1200/JCO.2002.10.018
Cell Cycle Analysis of a Cell Proliferation-Associated Human Nuclear Antigen Defined by the Monoclonal Antibody Ki-67, The Journal of Immunology, vol.133, issue.4, pp.1710-1725, 1984. ,
Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort, The Lancet, vol.375, issue.9712, pp.375-377, 2010. ,
DOI : 10.1016/S0140-6736(09)61964-4
5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial, The Lancet Oncology, vol.17, issue.6, pp.791-800, 2016. ,
DOI : 10.1016/S1470-2045(16)00163-7
Antiandrogen treatments in locally advanced prostate cancer: are they all the same?, Journal of Cancer Research and Clinical Oncology, vol.45, issue.S1, pp.17-26, 2006. ,
DOI : 10.1007/s00432-006-0133-5
Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013, Annals of Oncology, vol.24, issue.9, pp.2206-2229, 2013. ,
DOI : 10.1093/annonc/mdt303
Senn, and Panel members Strategies for Subtypes--Dealing with the Diversity of Breast Cancer: Highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011, Annals of Oncology: Official Journal of the European Society for Medical Oncology, issue.8, pp.22-1736, 2011. ,
Androgen Receptor Levels and Association with PIK3CA Mutations and Prognosis in Breast Cancer, Clinical Cancer Research, vol.15, issue.7, pp.2472-78, 2009. ,
DOI : 10.1158/1078-0432.CCR-08-1763
Phase II Trial of Bicalutamide in Patients with Androgen Receptor-Positive, Estrogen Receptor-Negative Metastatic Breast Cancer, Clinical Cancer Research, vol.19, issue.19, pp.5505-5517, 2013. ,
DOI : 10.1158/1078-0432.CCR-12-3327
A refined molecular taxonomy of breast cancer, Oncogene, vol.10, issue.9, pp.1196-1206, 2012. ,
DOI : 10.1038/nature09515
URL : https://hal.archives-ouvertes.fr/inserm-00611752
Molecular Subclasses of Breast Cancer: How Do We Define Them? The IMPAKT 2012, 2012. ,
A Three-Gene Model to Robustly Identify Breast Cancer Molecular Subtypes, JNCI Journal of the National Cancer Institute, vol.104, issue.4, pp.311-336, 2012. ,
DOI : 10.1093/jnci/djr545
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3283537
College Of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer, American Society of Clinical Oncology Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, vol.28, issue.16, pp.2784-95, 2010. ,
Novel Mutations of Androgen Receptor: A Possible Mechanism of Bicalutamide Withdrawal Syndrome, Cancer Research, vol.63, issue.1, pp.149-53, 2003. ,
Prognostic value of androgen receptor expression in operable triple-negative breast cancer: a retrospective analysis based on a tissue microarray, Medical Oncology, vol.4, issue.24, pp.406-416, 2012. ,
DOI : 10.1007/s12032-011-9832-0
Characterization of a Naturally Occurring Breast Cancer Subset Enriched in Epithelial-to-Mesenchymal Transition and Stem Cell Characteristics, Cancer Research, vol.69, issue.10, pp.4116-4140, 2009. ,
Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors, Genome Biology, vol.8, issue.5, pp.76-86, 2007. ,
DOI : 10.1186/gb-2007-8-5-r76
Early Discontinuation and Nonadherence to Adjuvant Hormonal Therapy in a Cohort of 8,769 Early-Stage Breast Cancer Patients, Journal of Clinical Oncology, vol.28, issue.27, pp.4120-4148, 2010. ,
DOI : 10.1200/JCO.2009.25.9655
Androgen Receptor Expression and Breast Cancer Survival in Postmenopausal Women Clinical Cancer Research, An Official Journal of the American Association for Cancer Research, vol.17, issue.7, pp.1867-74, 2011. ,
The Molecular Portraits of Breast Tumors Are Conserved across Microarray Platforms, BMC Genomics, vol.7, issue.1, pp.96-106, 2006. ,
DOI : 10.1186/1471-2164-7-96
Proposal for Standardized Definitions for Efficacy End Points in Adjuvant Breast Cancer Trials: The STEEP System, Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, vol.25, issue.15, pp.2127-2159, 2007. ,
Breast Cancer Subtypes and Response to Docetaxel in Node-Positive Breast Cancer: Use of an Immunohistochemical Definition in the BCIRG 001 Trial, Journal of Clinical Oncology, vol.27, issue.8, pp.1168-76, 2009. ,
DOI : 10.1200/JCO.2008.18.1024
New insights into the role of androgen and oestrogen receptors in molecular apocrine breast tumours, Breast Cancer Research, vol.364, issue.6, pp.318-328, 2011. ,
DOI : 10.1056/NEJMoa1014618
Estrogen Receptor (ER) mRNA and ER-Related Gene Expression in Breast Cancers That Are 1% to 10% ER-Positive by Immunohistochemistry, Journal of Clinical Oncology, vol.30, issue.7, pp.729-763, 2012. ,
DOI : 10.1200/JCO.2011.36.2574
Proteomic and bioinformatic analysis of mammalian SWI/SNF complexes identifies extensive roles in human malignancy, Nature Genetics, vol.460, issue.6, pp.592-601, 2013. ,
DOI : 10.1128/MCB.02019-07
Two Distinct Estrogen-Regulated Promoters Generate Transcripts Encoding the Two Functionally Different Human Progesterone Receptor Forms A and B, The EMBO Journal, vol.9, issue.5, pp.1603-1617, 1990. ,
Standardized Ki67 Diagnostics Using Automated Scoring--Clinical Validation in the GeparTrio Breast Cancer Study, Clinical Cancer Research, vol.21, issue.16, 2014. ,
DOI : 10.1158/1078-0432.CCR-14-1283
Tissue Microarrays for High-Throughput Molecular Profiling of Tumor Specimens, Nature Medicine, vol.4, issue.7, pp.844-891, 1998. ,
Statistical controversies in clinical research: assessing pathologic complete response as a trial-level surrogate end point for early-stage breast cancer, Annals of Oncology, vol.27, issue.1, pp.10-15, 2016. ,
DOI : 10.1093/annonc/mdv507
An F876L Mutation in Androgen Receptor Confers Genetic and Phenotypic Resistance to MDV3100 (Enzalutamide), Cancer Discovery, vol.3, issue.9, pp.1030-1073, 2013. ,
DOI : 10.1158/2159-8290.CD-13-0142
Semi-quantitative immunohistochemical assay versus oncotype DX?? qRT-PCR assay for estrogen and progesterone receptors: an independent quality assurance study, Modern Pathology, vol.19, issue.6, pp.869-76, 2012. ,
DOI : 10.3109/07357907.2010.496754
Functional domains of the human estrogen receptor, Cell, vol.51, issue.6, pp.941-51, 1987. ,
DOI : 10.1016/0092-8674(87)90581-2
International Agency for Research on Cancer, and World Health Organization WHO Classification of Tumours of the Breast World Health Organization Classification of Tumours, International Agency for Research on Cancer, 2012. ,
The androgen receptor as a surrogate marker for molecular apocrine breast cancer subtyping, The Breast, vol.23, issue.3, p.23, 2014. ,
DOI : 10.1016/j.breast.2014.02.013
Prognostic Value of Lymphovascular Invasion in Women with Lymph Node Negative Invasive Breast Carcinoma, European Journal of Cancer, vol.42, issue.3, pp.357-62, 2006. ,
Recent advances in androgen receptor action, Cellular and Molecular Life Sciences (CMLS), vol.60, issue.8, pp.1613-1635, 2003. ,
DOI : 10.1007/s00018-003-2309-3
Identification of Human Triple-Negative Breast, 2011. ,
PIK3CA mutations in androgen receptor-positive triple negative breast cancer confer sensitivity to the combination of PI3K and androgen receptor inhibitors, Breast Cancer Research, vol.19, issue.4, 2014. ,
DOI : 10.1158/1078-0432.CCR-12-3327
Molecular Apocrine Breast Cancers Are Aggressive Estrogen Receptor Negative Tumors Overexpressing Either HER2 or GCDFP15 Les Données -Institut National Du Cancer, Breast Cancer Research: BCR Accessed August, vol.15, issue.3, 2013. ,
DOI : 10.1186/bcr3421
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4053236
Response to Neoadjuvant Therapy and Long-Term Survival in Patients with Triple-Negative Breast Cancer, Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, vol.26, issue.8, pp.1275-81, 2008. ,
Importance of Breast Cancer Subtype in the Development of Androgen-Receptor-Directed Therapy, Current Breast Cancer Reports, vol.375, issue.9724, pp.71-78, 2014. ,
DOI : 10.1007/s12609-014-0140-5
Aberrant Luminal Progenitors as the Candidate Target Population for Basal Tumor Development in BRCA1 Mutation Carriers, Nature Medicine, vol.15, issue.8, pp.907-920, 2000. ,
Definition of Clinically Distinct Molecular Subtypes in Estrogen Receptor?Positive Breast Carcinomas Through Genomic Grade, Journal of Clinical Oncology, vol.25, issue.10, pp.1239-1285, 2007. ,
Androgen receptor expression in primary breast cancer and its predictive and prognostic value in patients treated with neoadjuvant chemotherapy, Breast Cancer Research and Treatment, vol.28, issue.6, pp.477-87, 2011. ,
DOI : 10.1007/s10549-011-1715-8
Outcomes of a Population-Based Series of Early Breast Cancer Patients with Micrometastases and Isolated Tumour Cells in Axillary Lymph Nodes, Annals of Oncology, vol.24, issue.11, pp.2794-2801, 2013. ,
Role of Androgens on MCF-7 Breast Cancer Cell Growth and on the Inhibitory Effect of Letrozole, Cancer Research, vol.66, issue.15, pp.7775-82, 2006. ,
[Pre-analytical stage for biomarker assessment in breast cancer: 2014 update of the GEFPICS' guidelines in France], 2014. ,
Microarray- Based Class Discovery for Molecular Classification of Breast Cancer: Analysis of Interobserver Agreement, Journal of the National Cancer Institute, vol.103, issue.8, pp.662-73, 2011. ,
Randomized Phase II Trial of the Efficacy and Safety of Trastuzumab Combined with Docetaxel in Patients with Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer Administered as First-Line Treatment: The M77001 Study Group, Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, vol.23, pp.4265-74, 2005. ,
Differential Response to Neoadjuvant Chemotherapy Among 7 Triple-Negative Breast Cancer Molecular Subtypes, Clinical Cancer Research, vol.19, issue.19, pp.5533-5573, 2013. ,
DOI : 10.1158/1078-0432.CCR-13-0799
Androgen receptor in triple negative breast cancer, The Journal of Steroid Biochemistry and Molecular Biology, vol.133, pp.66-76, 2013. ,
DOI : 10.1016/j.jsbmb.2012.08.007
Androgen Receptor Is Frequently Expressed in HER2-Positive, ER/PR- Negative Breast Cancers, Virchows Archiv: An International Journal of Pathology, vol.457, issue.4, 2010. ,
Preoperative chemotherapy for women with operable breast cancer, The Cochrane Database of Systematic Reviews, vol.30, issue.22, 2007. ,
DOI : 10.1002/14651858.CD005002
Tissue Micro-Array: A Cost and Time-Effective Method for Correlative Studies by Regional and National Cancer Study Groups, Modern Pathology, vol.15, issue.12, pp.1366-73, 2002. ,
DOI : 10.1097/01.MP.0000036345.18944.22
Pure Apocrine Carcinomas Represent a Clinicopathologically Distinct Androgen Receptor-Positive Subset of Triple-Negative Breast Cancers, The American Journal of Surgical Pathology, vol.40, issue.8, pp.1109-1125, 2016. ,
Definition and Impact of Pathologic Complete Response on Prognosis After Neoadjuvant Chemotherapy in Various Intrinsic Breast Cancer Subtypes, Journal of Clinical Oncology, vol.30, issue.15, pp.1796-1804, 2012. ,
Progesterone Receptor Modulates ER? Action in Breast Cancer, Nature, vol.523, issue.7560, pp.313-330, 2015. ,
Discovery of ODM-201, a New-Generation Androgen Receptor Inhibitor Targeting Resistance Mechanisms to Androgen Signaling-Directed Prostate Cancer Therapies, Scientific Reports, vol.5, p.12007, 2015. ,
Synergy between inhibitors of androgen receptor and MEK has therapeutic implications in estrogen receptor-negative breast cancer, Breast Cancer Research, vol.70, issue.2, pp.36-46, 2011. ,
DOI : 10.1158/0008-5472.CAN-09-1845
A Functionally Significant Cross-Talk between, 2008. ,
Tumour size predicts long-term survival among women with lymph node-positive breast cancer, Current Oncology, vol.19, issue.5, pp.249-53, 2012. ,
DOI : 10.3747/co.19.1043
URL : http://doi.org/10.3747/co.19.1043
Amplitude modulation of androgen signaling by c-MYC, Genes & Development, vol.27, issue.7, 2013. ,
DOI : 10.1101/gad.209569.112
Targeting Androgen Receptor in Estrogen Receptor-Negative Breast Cancer, Cancer Cell, vol.20, issue.1, pp.119-150, 2011. ,
Immunohistochemical and Clinical Characterization of the Basal-Like Subtype of Invasive Breast Carcinoma, Clinical Cancer Research, vol.10, issue.16, pp.5367-74, 2004. ,
DOI : 10.1158/1078-0432.CCR-04-0220
A Comparison of PAM50 Intrinsic Subtyping with Immunohistochemistry and Clinical Prognostic Factors in Tamoxifen-Treated Estrogen Receptor-Positive Breast Cancer Clinical Cancer Research, An Official Journal of the American Association for Cancer Research, vol.16, issue.21, pp.5222-5254, 2010. ,
Androgen receptor in breast cancer: expression in estrogen receptor-positive tumors and in estrogen receptor-negative tumors with apocrine differentiation, Modern Pathology, vol.10, issue.2, 2010. ,
DOI : 10.1016/S0002-9610(03)00054-0
Discovery and Development of Galeterone (TOK-001 or VN/124-1) for the Treatment of All Stages of Prostate Cancer, Journal of Medicinal Chemistry, vol.58, issue.5, pp.2077-87, 2015. ,
DOI : 10.1021/jm501239f
Adjuvant Exemestane with Ovarian Suppression in Premenopausal Breast Cancer, New England Journal of Medicine, vol.371, issue.2, pp.107-125, 2014. ,
DOI : 10.1056/NEJMoa1404037
Expression of androgen receptors in primary breast cancer, Annals of Oncology, vol.21, issue.3, pp.488-92, 2010. ,
DOI : 10.1093/annonc/mdp510
Supervised Risk Predictor of Breast Cancer Based on Intrinsic Subtypes, Journal of Clinical Oncology, vol.27, issue.8, pp.1160-67, 2009. ,
DOI : 10.1200/JCO.2008.18.1370
évaluation Du Statut HER2 Dans Les Cancers Du Sein En France, Annales de Pathologie, vol.34, issue.5, pp.352-65 ,
Molecular Portraits of Human Breast Tumours, Nature, vol.406, issue.6797, pp.747-52, 2000. ,
DOI : 10.1038/35021093
Molecular Portraits of Human Breast Tumours, Nature, vol.406, issue.6797, pp.747-52, 2000. ,
DOI : 10.1038/35021093
Classification and risk stratification of invasive breast carcinomas using a real-time quantitative RT-PCR assay, Breast Cancer Research, vol.65, issue.Part 3, pp.23-33, 1399. ,
DOI : 10.1158/0008-5472.CAN-04-3617
Androgen Receptor Inhibits Estrogen Receptor-Alpha Activity and Is Prognostic in Breast Cancer, Cancer Research, vol.69, issue.15, pp.6131-6171, 2009. ,
Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast Cancer, New England Journal of Medicine, vol.353, issue.16, pp.1659-72, 2005. ,
DOI : 10.1056/NEJMoa052306
Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer, Breast Cancer Research, vol.15, issue.1, pp.10-1186, 2010. ,
DOI : 10.1038/nm0809-842
Targeting the Androgen Receptor in Prostate and Breast Cancer: Several New Agents in Development, Endocrine-Related Cancer, vol.22, issue.3, pp.87-106, 2015. ,
Pathological Complete Response and Accelerated Drug Approval in Early Breast Cancer, New England Journal of Medicine, vol.366, issue.26, pp.2438-2479, 2012. ,
DOI : 10.1056/NEJMp1205737
Is it useful to detect lymphovascular invasion in lymph node-positive patients with primary operable breast cancer?, Cancer, vol.23, issue.suppl, pp.3093-3101, 2010. ,
DOI : 10.1002/cncr.25137
Prognostic Significance of Nottingham Histologic Grade in Invasive Breast Carcinoma, Journal of Clinical Oncology, vol.26, pp.3153-58, 2008. ,
Role of the Androgen Receptor in Triple-Negative Breast Cancer, Clinical Advances in Hematology & Oncology: H&O, vol.14, issue.3, pp.186-93, 2016. ,
Phase I Study of ARN-509, a Novel Antiandrogen, in the Treatment of Castration-Resistant Prostate Cancer, Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, issue.28, pp.31-3525, 2013. ,
Prognostic Significance of Progesterone Receptor Levels in Estrogen Receptor-Positive Patients with Metastatic Breast Cancer Treated with Tamoxifen: Results of a Prospective Southwest Oncology Group Study, Journal of Clinical Oncology, vol.10, issue.8, pp.1284-91, 1992. ,
AR Collaborates with ER? in Aromatase Inhibitor-Resistant Breast Cancer, Breast Cancer Research and Treatment, vol.147, issue.3, pp.473-85, 2014. ,
Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8??1 years median follow-up, The Lancet Oncology, vol.12, issue.12, pp.1101-1109, 2011. ,
DOI : 10.1016/S1470-2045(11)70270-4
Differential Gene Regulation by the Two Progesterone Receptor Isoforms in Human Breast Cancer Cells, Journal of Biological Chemistry, vol.277, issue.7, pp.5209-5227, 2002. ,
DOI : 10.1074/jbc.M110090200
Estrogen Receptor Beta as a Novel Target of Androgen Receptor Action in Breast Cancer Cell Lines, Breast Cancer Research: BCR, vol.16, issue.1, 2014. ,
Androgen Receptor Driven Transcription in Molecular Apocrine Breast Cancer Is Mediated by FoxA1, The EMBO Journal, vol.30, issue.15, pp.3019-3046, 2011. ,
Trastuzumab plus Adjuvant Chemotherapy for Operable HER2-Positive Breast Cancer, The New England Journal of Medicine, vol.353, issue.16, pp.1673-84, 2005. ,
Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy, The New England Journal of Medicine, vol.368, issue.2, 2013. ,
Influence of Tumour Stage at Breast Cancer Detection on Survival in Modern Times: Population Based Study in 173 797 Patients, The BMJ, vol.351, 2015. ,
Androgen Receptor (AR) Expression in 400 Breast Carcinomas: Is Routine AR Assessment Justified, 2014. ,
Gene expression meta-analysis supports existence of molecular apocrine breast cancer with a role for androgen receptor and implies interactions with ErbB family, BMC Medical Genomics, vol.32, issue.Unit 7, pp.59-69, 2009. ,
DOI : 10.1109/TSMCA.2002.803772
Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy, New England Journal of Medicine, vol.367, issue.13, pp.1187-97, 2012. ,
Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up, Annals of Oncology, vol.26, issue.suppl 5, pp.8-30, 2015. ,
DOI : 10.1093/annonc/mdv298
The significance of oncogene amplification in primary breast cancer, International Journal of Cancer, vol.47, issue.2, pp.270-72, 1989. ,
DOI : 10.1002/ijc.2910430218
The clonal and mutational evolution spectrum of primary triple-negative breast cancers, Nature, vol.464, issue.7403, pp.395-9910, 1038. ,
DOI : 10.1038/nature10933
Cancer statistics, 2015, CA: A Cancer Journal for Clinicians, vol.61, issue.3, pp.5-29, 2015. ,
DOI : 10.3322/caac.21254
The Role of Lymphovascular Invasion as a Prognostic Factor in Patients with Lymph Node-Positive Operable Invasive Breast Cancer, Journal of Breast Cancer, vol.14, issue.3, pp.198-203, 2011. ,
Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications, Proceedings of the National Academy of Sciences, vol.98, issue.19, pp.10869-74, 2001. ,
DOI : 10.1073/pnas.191367098
Repeated Observation of Breast Tumor Subtypes in Independent Gene Expression Data Sets, Proceedings of the National Academy of Sciences of the United States of America, vol.100, issue.14, pp.8418-8441, 2003. ,
The Landscape of Cancer Genes and Mutational Processes in Breast Cancer, Nature, vol.486, issue.7403, pp.400-404, 2012. ,
International Agency for Research on Cancer, and World Health Organization Pathology and Genetics of Tumours of the Breast and Female Genital Organs. World Health Organization Classification of Tumours, 2003. ,
Multifaceted interaction between the androgen and Wnt signaling pathways and the implication for prostate cancer, Journal of Cellular Biochemistry, vol.61, issue.2, pp.402-412, 2006. ,
DOI : 10.1002/jcb.20983
URL : https://hal.archives-ouvertes.fr/inserm-00106395
Adjuvant Paclitaxel and Trastuzumab for, 2015. ,
Positive Breast Cancer, The New England Journal of Medicine, vol.372, issue.2, pp.134-175, 1406281. ,
Anticancer Activity of a Novel Selective CYP17A1 Inhibitor in Preclinical Models of Castrate-Resistant Prostate Cancer, Molecular Cancer Therapeutics, vol.14, issue.1, pp.59-69, 2015. ,
DOI : 10.1158/1535-7163.MCT-14-0521
Development of a Second-Generation Antiandrogen for Treatment of Advanced Prostate Cancer, Science, vol.324, issue.5928, pp.324-787, 2009. ,
DOI : 10.1126/science.1168175
Non-Sentinel Lymph, 2008. ,
Androgen Receptor Expression and Outcomes in Early Breast Cancer: A Systematic Review and Meta-Analysis, Journal of the National Cancer Institute, vol.106, issue.1, 2014. ,
Predicting the Risk for Additional Axillary Metastases in Patients With Breast Carcinoma and Positive Sentinel Lymph Node Biopsy, Annals of Surgery, vol.241, issue.2, pp.319-344, 2005. ,
Immunohistochemical and molecular profiling of histologically defined apocrine carcinomas of the breast, Human Pathology, vol.46, issue.9, 2015. ,
DOI : 10.1016/j.humpath.2015.05.017
EGFR and HER-2/neu expression in invasive apocrine carcinoma of the breast, Modern Pathology, vol.33, issue.5, pp.644-53, 2010. ,
DOI : 10.1111/j.1699-0463.1999.tb01546.x
Constitutively active androgen receptor splice variants expressed in castration-resistant prostate cancer require full-length androgen receptor, Proceedings of the National Academy of Sciences, vol.107, issue.39, pp.16759-65, 2010. ,
DOI : 10.1073/pnas.1012443107
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2947883
Refinement of Breast Cancer Classification by Molecular Characterization of Histological Special Types, The Journal of Pathology, vol.216, issue.2, pp.141-50, 2008. ,
An Atlas of Subgross Pathology of the Human Breast with Special Reference to Possible Precancerous Lesions, Journal of the National Cancer Institute, vol.55, issue.2, pp.231-73, 1975. ,
Long-Term Results of Hypofractionated Radiation Therapy for Breast Cancer, New England Journal of Medicine, vol.362, issue.6, pp.513-533, 2010. ,
DOI : 10.1056/NEJMoa0906260
Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast CancerCollege of American Pathologists Clinical Practice Guideline Update, Journal of Clinical Oncology, vol.31, issue.31, pp.3997-4013, 2013. ,
JARID1B Is a Luminal Lineage-Driving Oncogene in Breast Cancer, Cancer Cell, vol.25, issue.6, pp.762-77, 2014. ,
DOI : 10.1016/j.ccr.2014.04.024
A Phase II Randomized, Double-Blind, Placebo-Controlled Multicenter Trial Evaluating the Efficacy and Safety of Enzalutamide in Combination with Exemestane in Estrogen or Progesterone Receptor-Positive and HER2- Normal Advanced Breast Cancer, Journal of Clinical Oncology, vol.32, p.5, 2014. ,
Identification of Prognosis-Relevant Subgroups in Patients with Chemoresistant Triple-Negative Breast Cancer, Clinical Cancer Research, vol.19, issue.10, pp.2723-2756, 2013. ,
DOI : 10.1158/1078-0432.CCR-12-2986